Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
Journal
Case Reports in Oncology
Journal Volume
9
Journal Issue
2
Pages
474-480
Date Issued
2016
Abstract
Maintenance pemetrexed offers survival benefit with well-tolerated toxicities for advanced non-squamous non-small cell lung cancer (NSCLC). We present 3 consecutively enrolled patients with advanced non-squamous NSCLC, receiving stereotactic ablative radiotherapy (SABR) for oligoprogressive disease during maintenance pemetrexed. All of them had sustained local control of thoracic oligoprogression after the SABR, while maintenance pemetrexed were kept for additionally long progression-free interval. SABR targeting oligoprogression with continued pemetrexed is an effective and safe approach to extend exposure of maintenance pemetrexed, thus maximizing the benefit from it. ? 2016 The Author(s). Published by S. Karger AG, Basel.
SDGs
Other Subjects
afatinib; cisplatin; erlotinib; gefitinib; gemcitabine; navelbine; pemetrexed; ablation therapy; adult; aged; anemia; Article; cancer radiotherapy; case report; computer assisted tomography; eosinophilia; fatigue; female; fever; gastrointestinal symptom; human; lung adenocarcinoma; lymphadenopathy; maintenance therapy; male; middle aged; multimodality cancer therapy; multiple cycle treatment; non small cell lung cancer; palliative therapy; priority journal; progression free survival; radiation dose; radiation injury; radiation pneumonia; spine metastasis; stereotactic treatment; treatment response; tumor volume
Publisher
S. Karger AG
Type
journal article